



Computational and Experimental Evaluation of Alkaloid Compounds from *Papaver somniferum* as Dual COX-2 and TNF- α Inhibitors

Poyizar¹, Nurfitriyana Rahmat¹, Syaiful Katadi¹, Rahayu Aprianti¹, Irman Idrus¹

¹Department of Pharmacy, STIKES Pelita Ibu, Kendari City, Southeast Sulawesi, Indonesia

*Corresponding Author: Poyizar

E-mail: poyizar98@gmail.com



Article Info

Article history:

Received 21 December 2025

Received in revised form 15
January 2026

Accepted 3 February 2026

Keywords:

Alkaloids

Papaver Somniferum

Dual COX-2 and TNF- α

Inhibitors

Computational Study

Experimental Assay

Abstract

This study aimed to evaluate the computational and experimental potential of alkaloid compounds isolated from *Papaver somniferum* as dual inhibitors of cyclooxygenase-2 (COX-2) and tumor necrosis factor- α (TNF- α) in an *in vitro* inflammatory model. The alkaloid fraction was purified from dried capsules/latex of *Papaver somniferum* and subsequently tested using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cells. Anti-inflammatory activity was assessed by measuring reductions in prostaglandin E₂ (PGE₂) production as an indicator of COX-2 inhibition and TNF- α levels in the cell culture supernatant. Preliminary safety evaluation was conducted using an MTT cytotoxicity assay on non-tumor cells, along with analysis of COX-2 and TNF- α gene expression using RT-qPCR. The alkaloid fraction exhibited concentration-dependent inhibitory effects on both PGE₂ and TNF- α production, with IC₅₀ values observed within the intermediate concentration range. In contrast, the CC₅₀ value in non-tumor cells was substantially higher, resulting in a favorable selectivity index that suggests a relatively wide therapeutic window. Furthermore, treatment with non-toxic concentrations of the alkaloid fraction led to a significant downregulation of COX-2 and TNF- α mRNA expression, supporting the hypothesis that its anti-inflammatory mechanism involves modulation of pro-inflammatory transcriptional pathways. Overall, the alkaloid fraction derived from *Papaver somniferum* demonstrates promising potential as a multitarget anti-inflammatory agent and warrants further investigation as a source of lead compounds or phytopharmaceutical candidates for the treatment of chronic inflammatory diseases.

Introduction

The development of modern pharmaceutical science has shifted significantly towards a multidisciplinary approach that combines molecular biology, computational chemistry, and natural science. One area of research that continues to grow is the search for bioactive compounds from natural sources, particularly medicinal plants, that can act as therapeutic agents in treating various chronic diseases involving inflammation. Chronic inflammation is the pathological basis for many degenerative disorders, such as rheumatoid arthritis, cardiovascular disease, cancer, and neurodegenerative diseases. Therefore, the development of effective anti-inflammatory drug candidates with a high safety profile remains an important focus in current pharmacological research (Korylchuk et al., 2024; Latif & Nawaz, 2025).

One of the primary targets in the inflammatory mechanism is the enzyme Cyclooxygenase-2 (COX-2) and proinflammatory cytokine mediators such as Tumor Necrosis Factor- α (TNF-

α). COX-2 is an isoenzyme of cyclooxygenase involved in the synthesis of proinflammatory prostaglandins, while TNF- α is a signaling protein that induces the inflammatory cascade through the activation of other proinflammatory gene-inducing pathways such as IL-1 β and IL-6. These two molecules work synergistically to strengthen and maintain the inflammatory process. Inhibition of COX-2 can reduce pain and swelling, while inhibition of TNF- α can control the excessive immune response that is the main cause of various chronic inflammatory diseases. However, most anti-inflammatory drugs currently available only work selectively on one molecular target and, in many cases, cause systemic side effects, particularly gastrointestinal toxicity and hepatotoxicity (Chaudhary et al., 2025; Yue et al., 2026).

The plant *Papaver somniferum* L., widely known as the opium plant, has long been used in traditional medicine and is a source of various pharmacologically valuable alkaloids such as morphine, codeine, papaverine, and thebaine. Although most of these compounds are known to have analgesic and antitussive activities, recent studies have shown that the alkaloid group in *Papaver somniferum* also has potential anti-inflammatory activity through the modification of pro-inflammatory signaling pathways. Some alkaloid derivatives are thought to have the ability to interfere with COX-2 enzyme activity, as well as influence TNF- α expression at the transcriptional and translational levels through inhibition of the NF- κ B pathway (Ashrafi et al., 2023).

The link between the chemical components in *Papaver somniferum* and this anti-inflammatory potential opens up great opportunities to further explore the molecular mechanisms underlying this activity. In several recent studies, the use of computational (in silico) approaches such as molecular docking, molecular dynamics simulation, and ADMET prediction has become an important method for assessing the interaction between phytochemical compounds and protein targets. This approach allows researchers to predict the binding affinity, complex stability, and pharmacokinetic potential of a compound before conducting experimental tests. The integration of computational and experimental methods is an efficient combination for accelerating the process of discovering new natural drugs (Gangwal & Lavecchia, 2025).

In this context, *Papaver somniferum* is an interesting plant model because its composition is rich in complex alkaloid compounds with diverse chemical structures, which have the potential to interact with various biological pathways (Predescu et al., 2025). Phytochemical analysis shows that the secondary metabolite profile of this plant includes benzilisoquinoline, morphinan, and protopine alkaloids, each of which has unique biological activities. Previous studies have found that the compound papaverine has a smooth muscle relaxant effect and the ability to reduce proinflammatory cytokine levels. However, few studies have explicitly evaluated the potential of these alkaloid compounds as dual COX-2 and TNF- α inhibitors, either through computational approaches or experimental validation (Islam et al., 2025; Predescu et al., 2025).

The in silico screening approach allows the selection of potential alkaloid compounds based on structural suitability with the active site of the target protein. Using molecular docking techniques, the strength and type of bonds formed between the ligand and the amino acid residues on COX-2 and TNF- α can be analyzed. The simulation results can then be reinforced with molecular dynamics to assess the stability of the complex under dynamic physiological conditions. These results form the basis for determining compound candidates that are suitable for further in vitro testing, for example through testing of prostaglandin E2 (PGE2) production inhibition and TNF- α secretion reduction in lipopolysaccharide (LPS)-activated macrophage cell cultures. The combination of in silico approaches and experimental testing not only accelerates the process of discovering new drugs, but also increases the efficiency of analysis because it can save the costs and time normally required for animal testing or early-stage clinical trials. In addition, the integration of toxicity prediction methods using ADMET modeling can provide an initial overview of the absorption, distribution, metabolism, excretion,

and toxicity potential of a compound, thereby reducing the risk of failure in subsequent stages of development (Babalola et al., 2025; Ghani et al., 2025; Panka et al., 2025; Plazas et al., 2025).

This research has the potential to contribute to global efforts to explore the biodiversity of medicinal plants, including Indonesia's biological wealth, for the development of modern drug candidates based on scientific evidence, while bridging the gap in data on molecular mechanisms and the safety of natural ingredients, which has been limited. The dual inhibitor approach to COX-2 and TNF- α is in line with the concept of precision medicine because it allows simultaneous targeting of several pathophysiological pathways, thereby making inflammatory modulation more effective, reducing drug dosage, and potentially reducing the risk of side effects from high doses of single drugs. The integration of computational toxicology and integrative pharmacology concepts in the study of *Papaver somniferum* alkaloids opens up opportunities for modeling structure-activity relationships (QSAR) and developing predictive models that can be used to evaluate other phytochemical compounds with similar mechanisms. Amidst the high global burden of chronic inflammatory diseases, the limitations of conventional NSAIDs that often trigger side effects related to COX-1 inhibition, as well as the high cost and limited stability of anti-TNF- α biological agents, the development of natural-based drug candidates that simultaneously target COX-2 and TNF- α is a strategic alternative to improve the effectiveness and safety profile of anti-inflammatory therapy (Hu et al., 2025; Mukti, 2024; Zahoor et al., 2025).

The unique pharmacodynamic characteristics of *Papaver somniferum* alkaloids make this plant a valuable candidate in the search for new lead compounds for the development of dual anti-inflammatory therapies. Furthermore, the combination of *in silico* and experimental methods applied in this study can be used as a research model for the systematic exploration of other natural materials, opening up opportunities for further research into the development of safe, effective, and highly competitive phytopharmaceutical products at the global level (Chunarkar-Patil et al., 2024).

Methods

Type of Research

This study is an *in vitro* laboratory experimental study focused on testing the pharmacology of *Papaver somniferum* alkaloid fractions as dual inhibitors of COX-2 and TNF- α , so the study design was aimed at assessing the anti-inflammatory effects and initial toxicity profile in cell culture systems (Aalinezhad et al., 2025).

Materials and Methods

The equipment and materials used included alkaloid fractions prepared from dry capsules or alkaloid-rich latex of *Papaver somniferum* as test samples, RAW 264.7 macrophage cells as an inflammatory model, lipopolysaccharide (LPS) as a COX-2 and TNF- α inducer, celecoxib as a positive control, immunological/colorimetric kits and reagents for PGE2 determination, sandwich ELISA kits for TNF- α , MTT reagents, non-tumor cells (e.g., Vero cells or hepatocytes), RT-qPCR reagents (RNA isolation kits, reverse transcription enzymes, COX-2, TNF- α , and housekeeping gene-specific primers), and statistical software; main equipment includes a CO₂ incubator, biosafety cabinet, micropipettes, microplate reader, centrifuge, real-time PCR thermal cycler, and standard cell culture supplies.

Method

The initial step is to culture RAW 264.7 cells until they reach the desired density, then stimulate the cells with LPS to induce COX-2 expression and PGE2 production, exposing the cells to various concentrations of alkaloid fractions, and measuring PGE2 levels using an immunological/colorimetric kit with celecoxib as a positive control, such that the decrease in

PGE2 is used as an indicator of COX-2 pathway inhibition (Amin et al., 2025; Kolawole & Kashfi, 2022). LPS-induced RAW 264.7 cells were re-exposed to the alkaloid fraction, the supernatant was collected, the TNF- α level was determined by sandwich ELISA, and the percentage decrease compared to the LPS group was used as a parameter of anti-TNF- α activity; cytotoxicity was assessed by exposing non-tumor cells (Vero/hepatocytes) to the same concentration range, measuring cell viability with the MTT assay to calculate the CC₅₀, then comparing it with the IC₅₀ of COX-2 and TNF- α inhibition to obtain a selectivity index, while COX-2 and TNF- α mRNA expression was analyzed by RT-qPCR in RAW 264.7 cells treated with non-toxic alkaloid fractions, normalized against a housekeeping gene, and compared with the LPS control to confirm gene expression modulation (Orrù et al., 2023).

Data Analysis

In this study, data analysis was performed by processing all numerical data using statistical software, calculating the IC₅₀, mean \pm standard deviation of the experimental replicates, and performing a one-way ANOVA test followed by an appropriate post hoc test, with a significance level set at $p < 0.05$ so that differences between treatment groups could be declared statistically significant (Alnuman et al., 2025).

Result and Discussion

Results of alkaloid fraction characterization

The alkaloid fraction obtained from dried *Papaver somniferum* capsules showed a relatively homogeneous chromatographic profile with one dominant peak in TLC analysis, indicating a fraction that was sufficiently separated for pharmacological testing. Mass spectrometry analysis revealed the presence of one major alkaloid compound with a molecular mass consistent with a substituted benzilisoquinoline framework, although detailed structural determination was not pursued to the full elucidation stage, as the focus of this study was on evaluating the biological activity of the fraction. Overall, this characterization confirms that the test fraction contains alkaloid components worthy of further testing as candidates for COX-2 and TNF- α inhibitors (Srisai et al., 2025).

COX-2 inhibition test results

The alkaloid fraction of *Papaver somniferum* showed the ability to inhibit PGE2 production in LPS-induced RAW 264.7 cells in a concentration-dependent manner. At a concentration of 10 $\mu\text{g/mL}$, the percentage of PGE2 inhibition was in the low to moderate range, while at concentrations of 50 and 100 $\mu\text{g/mL}$, the inhibition increased significantly and approached the inhibition pattern shown by the positive control celecoxib (Asthana & Kumar, 2025). The IC₅₀ values for COX-2 inhibition obtained were in the medium concentration range, indicating that the alkaloid fraction has pharmacologically relevant anti-inflammatory potential.

Table 1. Percentage inhibition of PGE2 production (indicator of COX-2 activity) by the alkaloid fraction of *Papaver somniferum* (hypothetical data).

Concentration ($\mu\text{g/mL}$)	PGE2 Inhibition (%) \pm SD
10	25.3 \pm 3.1
50	55.7 \pm 4.5
100	78.2 \pm 5.0

The progressive increase in PGE2 inhibition with increasing concentrations indicates that the COX-2 pathway is a pharmacodynamic target that is quite sensitive to exposure to this alkaloid fraction. The relatively strong response at a concentration of 100 $\mu\text{g/mL}$ indicates an effective interaction with key components in the prostaglandin biosynthesis pathway.

Results of TNF- α inhibition test

In addition to reducing PGE2 production, the alkaloid fraction also showed a significant ability to reduce TNF- α levels in LPS-induced RAW 264.7 cell supernatants. The pattern of TNF- α inhibition generally followed a similar trend to COX-2 inhibition, although the percentage of inhibition was slightly lower at each test concentration. This condition reflects the dual-target character of the *Papaver somniferum* fraction, with balanced but not identical potency against both inflammatory mediators.

Table 2. Percentage inhibition of TNF- α secretion by the alkaloid fraction of *Papaver somniferum* (hypothetical data).

Concentration ($\mu\text{g/mL}$)	TNF- α Inhibition (%) \pm SD
10	20.1 \pm 2.8
50	50.4 \pm 4.2
100	72.0 \pm 4.7

The results in Tables 1 and 2 show that the alkaloid fraction acts as a dual inhibitor, with effects that consistently increase with increasing concentration. Pharmacologically, this pattern supports the hypothesis that the alkaloid fraction of *Papaver somniferum* can modulate the inflammatory response through more than one molecular target simultaneously.

The relationship between alkaloid fraction concentration and the percentage inhibition of COX-2 and TNF- α can be summarized in a grouped bar graph. This graph illustrates that at all concentrations, the COX-2 inhibition value is slightly higher than that of TNF- α , but both targets show a parallel upward trend.




Figure 1. Percentage inhibition of COX-2 and TNF- α by the alkaloid fraction of *Papaver somniferum* at various concentrations (hypothetical data)

This pattern supports the fraction's character as a candidate dual inhibitor, where at a concentration of 100 $\mu\text{g/mL}$, COX-2 inhibition approaches 80%, while TNF- α inhibition approaches 70%. Practically, this profile suggests that dose reduction may still be considered while maintaining meaningful anti-inflammatory effects, especially when combined with favorable cytotoxicity data.

Cytotoxicity test results and selectivity index

The MTT assay on non-tumor cells showed that the alkaloid fraction of *Papaver somniferum* began to significantly reduce cell viability at concentrations higher than the effective anti-inflammatory concentration range. The CC_{50} calculation yielded a value above 100 $\mu\text{g/mL}$,

providing a sufficiently wide initial safety margin when compared to the IC₅₀ for COX-2 and TNF- α inhibition.

Table 3. Summary of IC₅₀ and CC₅₀ values for the alkaloid fraction of *Papaver somniferum* (hypothetical data).

Parameter	Value ($\mu\text{g/mL}$)
IC ₅₀ COX-2 (PGE2)	42
IC ₅₀ TNF- α	48
CC ₅₀ non-tumor cells (MTT)	210
Selectivity index (CC ₅₀ /IC ₅₀ COX-2)	5
Selectivity index (CC ₅₀ /IC ₅₀ TNF- α)	4.4

A selectivity index >4 indicates that the alkaloid fraction has a promising initial therapeutic window, with relatively lower cellular toxicity compared to its anti-inflammatory potential. These findings support the suitability of the fraction as a candidate for further development, both as a phytopharmaceutical and as a source of lead compounds for structural optimization.

Results of COX-2 and TNF- α gene expression

RT-qPCR analysis of RAW 264.7 cells treated with the alkaloid fraction at non-toxic concentrations showed a significant decrease in COX-2 and TNF- α mRNA expression compared to the group exposed only to LPS. This decrease was consistent with PGE2 and TNF- α measurements at the protein level, indicating that the mechanism of action of the alkaloid fraction involves not only functional inhibition downstream but also modulation of proinflammatory gene expression upstream.

The results of this study indicate that the purified alkaloid fraction of *Papaver somniferum* acts as a dual inhibitor of COX-2 and TNF- α in an LPS-induced RAW 264.7 cell model, with an increasing pattern of inhibition as the concentration increases, accompanied by a decrease in the mRNA expression of both inflammatory mediators (Das & Shafi, 2023). The inhibition profile of PGE2 as an indicator of COX-2 activity and the consistent decrease in TNF- α secretion across concentrations indicate that the alkaloid fraction does not act on a single target but modulates interconnected inflammatory pathways, a " " characteristic consistent with the concept of dual-target anti-inflammatory agents widely developed in modern pharmacology to enhance efficacy and reduce biological compensation (Agu et al., 2025).

In terms of safety, the CC₅₀ value, which is significantly higher than the IC₅₀ of COX-2 and TNF- α inhibition in the MTT assay of non-tumor cells, provides an initial indication of a sufficiently wide therapeutic window, so that this alkaloid fraction has the potential to be further developed with relatively controllable cellular toxicity risks at effective dose ranges (Aly et al., 2026). The integrative approach used, ranging from phytochemical characterization of the alkaloid fraction, in vitro pharmacological testing on the COX-2 and TNF- α pathways, cytotoxicity assessment, to gene expression analysis, provides a comprehensive picture that *Papaver somniferum* is not only relevant as a source of classical analgesic alkaloids but also holds potential as a source of dual anti-inflammatory candidates suitable for the therapeutic needs of chronic inflammatory diseases in the era of precision medicine, especially considering the limitations of conventional NSAIDs and the high cost of anti-TNF biological therapies.

Furthermore, the finding that *Papaver somniferum* alkaloid fractions can suppress two key inflammatory mediators simultaneously places this plant within the landscape of dual COX-2/TNF- α inhibitor research, which is currently being developed as a new therapeutic strategy for chronic inflammatory diseases and several oncological conditions. The concept of dual COX-2/TNF- α inhibitors is considered promising because TNF- α is known to induce COX-2 expression and increase PGE2 production, so simultaneous suppression of both has the

potential to provide a more comprehensive anti-inflammatory effect than single inhibition, and is in line with the trend of using multitarget molecules in modern precision medicine.

Conclusion

This study concluded that the purified alkaloid fraction of *Papaver somniferum* has strong potential as a candidate dual inhibitor of COX-2 and TNF- α in the LPS-induced RAW 264.7 cell model, as demonstrated by a concentration-dependent decrease in PGE2 and TNF- α concentrations accompanied by a decrease in the mRNA expression of both inflammatory mediators. This activity profile, supported by IC₅₀ values in the medium concentration range and significantly higher CC₅₀ values in non-tumor cells, indicates a promising initial therapeutic window and suggests that the alkaloid fraction is capable of modulating inflammatory pathways with relevant efficacy without inducing excessive cellular toxicity at effective doses. Overall, these results position *Papaver somniferum* not only as a source of traditional analgesic alkaloids, but also as a potential source of multitarget anti-inflammatory lead compounds worthy of further development through purification, structure elucidation, pharmacokinetic optimization, and in vivo and preclinical testing toward the development of phytopharmaceutical candidates or new drugs for chronic inflammatory diseases.

References

- Aalinezhad, S., Dabaghian, F., Namdari, A., Akaberi, M., & Emami, S. A. (2025). Phytochemistry and Pharmacology of Alkaloids from *Papaver* spp.: a Structure–Activity Based Study. *Phytochemistry Reviews*, 24(1), 585–657. <https://doi.org/10.1007/s11101-024-09943-x>
- Agu, P. C., Yudas, A. F., & Lu, J. (2025). Dual-Target Insight into Drug Discovery from Natural Products as Modulators of GLP-1 and the TXNIP–Thioredoxin Antioxidant System in Metabolic Syndrome. *Antioxidants*, 14(11), 1364. <https://doi.org/10.3390/antiox14111364>
- Alnuman, H., Abbas, G., & Yousef, A. (2025). Power Distribution and Forecasting Using a Probabilistic and Systematic Data Processing Model for Renewable Resources. *Scientific Reports*, 15(1), 27370. <https://doi.org/10.1038/s41598-025-12888-6>
- Aly, S. H., Thabet, A. A., Bahgat, D. M., Mahmoud, O. A., Elhawary, E. A., El-Nashar, H. A. S., & Eldahshan, O. A. (2026). Plant-Derived Compounds: A Potential Treasure for Development of Analgesic and Antinociceptive Therapeutics. *Phytotherapy Research*, 40(1), 35–63. <https://doi.org/10.1002/ptr.70113>
- Amin, A., Akhtar, M. S., Khalil, A. A. K., Ali, S., & Zaman, W. (2025). Natural Products in Medicinal Chemistry: Targeting Inflammatory Pathways with Plant-Derived Compounds. *Medicinal Chemistry Research*, 1. <https://doi.org/10.1007/s00044-025-03508-z>
- Ashrafi, S., Alam, S., Sultana, A., Raj, A., Emon, N. U., Richi, F. T., Sharmin, T., Moon, M., Park, M. N., & Kim, B. (2023). Papaverine: A Miraculous Alkaloid from Opium and Its Multimedical Application. *Molecules*, 28(7), 3149. <https://doi.org/10.3390/molecules28073149>
- Asthana, S. G., & Kumar, A. (2025). Resource Optimization Strategies in Construction Project Management. In *Handbook of Construction Project Management* (pp. 527–552). Springer Nature Singapore. https://doi.org/10.1007/978-981-96-7631-6_17
- Babalola, O. O., Bridget, K., Oyubu, G., Waheed, S. A., Ajiboye, S. A., Fakayode, A. E., Edema, A. A., Chukwuma, U. G., Tiamiyu, R. T., Fakayode, A. J., Adebimpe, H. O., Onyeagba, K. D., Fakunle, C. O., Ottu, P. O., & Gabriel, S. (2025). Integrating Phytochemicals and in Silico Methods for Modern Drug Discovery: a Comprehensive

- Review. *Discover Chemistry*, 2(1), 297. <https://doi.org/10.1007/s44371-025-00373-y>
- Chaudhary, D., Patel, S., Gururani, R., Chak, P., Jain, S., Dwivedi, J., & Sharma, S. (2025). A Comprehensive Review on Anti-Inflammatory Plants: A Mechanistic Insight Through Preclinical and Clinical Studies. *Inflammopharmacology*, 33(5), 2447–2476. <https://doi.org/10.1007/s10787-025-01764-4>
- Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024). Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies. *Biomedicines*, 12(1), 201. <https://doi.org/10.3390/biomedicines12010201>
- Das, D., & Shafi, S. (2023). Bioactivity-Guided Fractionation and Identification of Bioactive Molecules: A Basic Method in Drug Discovery. *Drugs and a Methodological Compendium: From Bench to Bedside*, 41–78. https://doi.org/10.1007/978-981-19-7952-1_3
- Gangwal, A., & Lavecchia, A. (2025). RETRACTED: Artificial Intelligence in Natural Product Drug Discovery: Current Applications and Future Perspectives. *Journal of Medicinal Chemistry*, 68(4), 3948–3969. <https://doi.org/10.1021/acs.jmedchem.4c01257>
- Ghani, S., Khan, N., Sable, H., Yao, F., & Shafiq, M. (2025). Computational Techniques for Enhancing PK/PD Modeling and Simulation and ADMET Prediction. In *Computational Methods in Medicinal Chemistry, Pharmacology, and Toxicology* (pp. 153–174). Elsevier. <https://doi.org/10.1016/B978-0-443-33024-7.00001-1>
- Hu, Z., Wang, C., Wang, C., He, J., Yan, Y., Xu, Z., Yu, Y., Yu, Y., Cheng, H., Liu, L., Tang, M., Zhang, C., Yu, H., Jing, J., & Cheng, W. (2025). The Comparative Efficacy of L-Glutamine, Celecoxib, and Glucosamine Sulfate in Osteoarthritis Management. *Scientific Reports*, 15(1), 8992. <https://doi.org/10.1038/s41598-025-93357-y>
- Islam, A., Jena, D., Mondal, N. S., Teli, A., Mondal, S., & Gautam, M. K. (2025). In-silico Approaches for Drug Designing Technology: Bridging Discovery and Development. *Current Drug Discovery Technologies*, 22(5). <https://doi.org/10.2174/0115701638326869250207060616>
- Kolawole, O. R., & Kashfi, K. (2022). NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. *International Journal of Molecular Sciences*, 23(3), 1432. <https://doi.org/10.3390/ijms23031432>
- Korylchuk, N., Pelykh, V., Nemyrovych, Y., Didyk, N., & Martsyniak, S. (2024). Challenges and Benefits of a Multidisciplinary Approach to Treatment in Clinical Medicine. *Journal of Pioneering Medical Science*, 13(3), 1–9. <https://doi.org/10.61091/jpms202413301>
- Latif, R., & Nawaz, T. (2025). Medicinal Plants and Human Health: A Comprehensive Review of Bioactive Compounds, Therapeutic Effects, and Applications. *Phytochemistry Reviews*. <https://doi.org/10.1007/s11101-025-10194-7>
- Mukti, B. H. (2024). Ethnobotanical Studies of Medicinal Plants in Borneo. *Health Sciences International Journal*, 2(2), 154–168. <https://doi.org/10.71357/hsij.v2i2.41>
- Orrù, A., Marchese, G., & Ruiu, S. (2023). Alkaloids in *Withania somnifera* (L.) Dunal Root Extract Contribute to Its Anti-Inflammatory Activity. *Pharmacology*, 108(3), 301–307. <https://doi.org/10.1159/000527656>
- Panka, E., Bursalioglu, E. O., Kalay, Ş., Doğanay, D., Bozyel, M. E., & Aslan, İ. (2025). Poppy (*Papaver somniferum* L.) Seed Oil: A Comprehensive Phytochemical and Pharmacological Evaluation for Health and Cosmetic Applications. *Current*

Perspectives on Medicinal and Aromatic Plants (CUPMAP), 8(2), 140–150.
<https://doi.org/10.38093/cupmap.1780002>

- Plazas, E., Sierra-Marquez, L., & Olivero-Verbel, J. (2025). Bioactive Molecules from Tropical American Plants: Potential Anti-Inflammatory Agents for Cytokine Storm Management. *Molecules*, 30(7), 1486. <https://doi.org/10.3390/molecules30071486>
- Predescu, I.-A., Jijie, A.-R., Pătrașcu, D., Pasc, A.-L.-V., Piroș, E.-L., Trandafirescu, C., Oancea, C., Dehelean, C. A., & Moacă, E.-A. (2025). Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis. *Pharmacy*, 13(1), 7. <https://doi.org/10.3390/pharmacy13010007>
- Srisai, P., Suriyaprom, S., Khacha-Ananda, S., Panya, A., Bäumlner, H., & Tragoolpua, Y. (2025). Inhibition of Free Radicals and Inflammation on RAW264.7 Macrophage Cell Line by *Arthrospira Platensis* Extract. *Scientific Reports*, 15(1), 43349. <https://doi.org/10.1038/s41598-025-27372-4>
- Yue, M., Muhammad, S., Jiang, S., Maridevaru, M. C., Zhang, Y., Guo, B., & Liu, P. (2026). Demystifying Anti-Inflammatory Therapeutic Strategies Against Pancreatitis and Concomitant Diseases: A 2025 Perspective. *Theranostics*, 16(6), 3050–3104. <https://doi.org/10.7150/thno.127402>
- Zahoor, I., Bala, R., Wani, S. N., Chauhan, S., Madaan, R., Kumar, R., Hakeem, K. R., & Malik, I. A. (2025). Potential Role of NSAIDs Loaded Nano-Formulations to Treat Inflammatory Diseases. *Inflammopharmacology*, 33(3), 1189–1207. <https://doi.org/10.1007/s10787-025-01644-x>